Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance of [14C]-ETC-1002 in healthy volunteers
NCT02044627Phase 1Completed
- Sponsor
- Esperion Therapeutics
- Start
- Dec 2013
- Primary completion
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bempedoic acid in hyperlipidemia, sponsored by Esperion Therapeutics. Primary endpoint: Level of [14C]-ETC-1002 in urine and feces at 11 days. Started Dec 2013; status: completed.
02
Drugs
bempedoic acid
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT02044627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044627.